Your session is about to expire
← Back to Search
Other
ATH-1017 for Alzheimer's Disease (LIFT-AD Trial)
Phase 2 & 3
Waitlist Available
Research Sponsored by Athira Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Are you not currently taking a medication called memantine (Namenda)?
Are you not currently participating in another clinical trial involving an investigational treatment?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 26
Awards & highlights
LIFT-AD Trial Summary
This trial will test a new drug for Alzheimer's disease to see if it is safe and effective. It will last 26 weeks.
Eligible Conditions
- Alzheimer's Dementia
- Alzheimer's Disease
LIFT-AD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
You are not currently taking a drug called memantine (Namenda).
Select...
You are not currently enrolled in another study testing an experimental treatment.
Select...
Do you have someone who can help you take the trial drug (fosgonimeton or placebo) every day and stay with you during the trial?
Select...
You are not taking any medications like Aricept, Exelon or Namzaric that are classified as acetylcholinesterase inhibitors.
Select...
You must be between the ages of 55 and 85 to participate.
Select...
You have been diagnosed by a doctor with mild or moderate Alzheimer's disease.
LIFT-AD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 26
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 26
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To evaluate the clinical efficacy of ATH1017 in subjects not on background acetylcholinesterase inhibitors (AChEIs)
Secondary outcome measures
Activities of Daily Living
Cognition
To determine the effect of ATH1017 on plasma neurofilament light chain (NfL) concentration
Side effects data
From 2022 Phase 2 trial • 77 Patients • NCT0449100663%
Injection site reaction
22%
Eosinophilia
15%
Pruritus
15%
Headache
15%
Injection site vesicles
15%
Fatigue
11%
Injection site pain
11%
Arthralgia
11%
Paraesthesia
7%
Neutrophilia
7%
Injection site erythema
7%
Lipohypertrophy
7%
Fall
7%
Dizziness
7%
Contusion
7%
Post procedural complication
7%
Pollakiuria
4%
Injection site induration
4%
Back pain
4%
Skin exfoliation
4%
Hyperlipidaemia
4%
Application site pruritus
4%
Genital paraesthesia
4%
Injection site pruritus
4%
Induration
4%
Dementia Alzheimer's type
4%
Injection site paraesthesia
4%
Immediate post-injection reaction
4%
Syncope
4%
Vomiting
4%
Rash pruritic
4%
Agitation
4%
Anaemia
4%
White blood cell count increased
4%
Urticaria
4%
Pruritus allergic
4%
Hypoglycaemia
4%
Electrocardiogram QT prolonged
4%
Hypotension
4%
Eosinophil count increased
4%
Amaurosis fugax
4%
Pneumonia aspiration
4%
Feeling abnormal
4%
Extensor plantar response
4%
Hip fracture
4%
Cholinergic syndrome
4%
Injection site mass
4%
Chest discomfort
4%
Flushing
4%
Parosmia
4%
Thrombocytopenia
4%
Nausea
4%
Diarrhoea
4%
Toothache
4%
Abdominal pain upper
4%
Skin abrasion
4%
Joint injury
4%
Skin induration
4%
Disorientation
4%
Delirium
4%
Upper respiratory tract infection
4%
Vertigo
4%
Lung disorder
4%
Dysphemia
4%
Wound secretion
4%
Pain
4%
Hair colour changes
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
ATH-1017 40 mg
ATH-1017 70 mg
LIFT-AD Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: DosageExperimental Treatment1 Intervention
Daily subcutaneous (SC) injection of 40mg ATH-1017
Group II: PlaceboPlacebo Group1 Intervention
Daily subcutaneous (SC) injection of Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ATH-1017
2020
Completed Phase 2
~80
Who is running the clinical trial?
Athira PharmaLead Sponsor
6 Previous Clinical Trials
683 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are not currently taking a drug called memantine (Namenda).You have been diagnosed by a doctor with mild or moderate Alzheimer's disease.You are not currently enrolled in another study testing an experimental treatment.Do you have someone who can help you take the trial drug (fosgonimeton or placebo) every day and stay with you during the trial?You must be between the ages of 55 and 85 to participate.You are not taking any medications like Aricept, Exelon or Namzaric that are classified as acetylcholinesterase inhibitors.
Research Study Groups:
This trial has the following groups:- Group 1: Dosage
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Alzheimer's Dementia Patient Testimony for trial: Trial Name: NCT04488419 — Phase 2 & 3
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
New York
California
Illinois
Other
What site did they apply to?
ATP Clinical Research, Inc
Neurology Center of North Orange County
Rush Alzheimer's Disease Center, Rush University Medical Center
Other
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
3+
1
0
What questions have other patients asked about this trial?
How long will screening take? Where are the trial locations? How long do test screenings take?
PatientReceived 2+ prior treatments
what is the commitment timeframe? Are there facilities close to my home?
PatientReceived 1 prior treatment
Why did patients apply to this trial?
My mother has the disease. i want to make a difference. Alzheimers runs in the family.
PatientReceived no prior treatments
I am memory issues occasionally. I have not any drugs for Alzheimers.
PatientReceived 1 prior treatment
How responsive is this trial?
Most responsive sites:
- Rush Alzheimer's Disease Center, Rush University Medical Center: < 24 hours
- ATP Clinical Research, Inc: < 24 hours
- Mile High Research Center: < 24 hours
Typically responds via
Email
Phone Call
Average response time
- < 2 Days
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger